retatrutide chills 30 Days of — LessWrong Retatrutide side effects: What to

Ageing Res Rev 112: 102834

Although investor concerns about the MedTech Sector have been based on expected declines in obesity rates with the surging adoption of GLP-1s, IQVIA MedTechs analysis of the data tells a different story, overall, that - to date - obesity diagnoses remain stable during the rise of GLP-1 uptake as depicted below: As a result, the resilience of obesity diagnosis occurring despite the rising uptake of GLP-1s should serve as a positive general signal for MedTech industry players to counter investor concerns about the potential of reduced demand, or that the demand may be net-neutral, rather than a sudden decline

Disclosures Anahi Perlas performs consulting work for Fujifilm Sonosite and receives peer-reviewed funding from the SHS-UHN Innovation Fund Award and a Womens College Hospital Innovation Fund Award (both, Toronto, ON, Canada)

It is about maintaining capability and resilience as the body changes

Eur J Biochem 214:829835 Seino Y, Fukushima M, Yabe D (2010) GIP and GLP-1, the two incretin hormones: similarities and differences